Medication instructions for Nintedanib in Laos
Nintedanib is a multi-target tyrosine kinase inhibitor mainly used for the treatment of idiopathic pulmonary fibrosis (IPF). It is necessary to strictly follow dosage specifications, monitor liver function, and adjust medication for special populations, with a focus on risks such as liver injury, gastrointestinal reactions, and embryotoxicity.
1. Usage and dosage
(1) Standard dose: 150mg orally, twice a day (with an interval of about 12 hours), taken whole with meals, not chewed or crushed.
(2) Omission treatment: No need for supplementation, administer according to the next scheduled time, with a maximum daily dose not exceeding 300mg.
(3) Reduction adjustment: Mild liver dysfunction patients should reduce to 100mg twice a day, and moderate to severe liver dysfunction patients should avoid using it.
2. Pre medication testing
(1) All patients need to undergo liver function testing (ALT/AST/bilirubin), and women of childbearing age need to confirm their pregnancy status.
(2) Monitor liver function monthly for the first 3 months of treatment. If symptoms of liver injury (such as jaundice) occur, immediate follow-up is required.
3. Adverse reaction management
(1) Diarrhea: Early use of antidiarrheal medication. If diarrhea persists, reduce dosage or suspend treatment. In severe cases, discontinue medication permanently.
(2) Nausea and vomiting: If the symptoms persist, consider reducing the dosage to 100mg twice a day. If the symptoms do not improve, discontinue medication.
(3) Elevated liver enzymes: mostly reversible, with higher risk in Asians, women, and low weight patients.
4. Taboos and Caution
(1) Pregnant women are prohibited from using it, and women of childbearing age should use effective contraception during treatment and within 3 months after discontinuing the medication.
(2) Use with caution in recent abdominal surgeries, diverticulitis, or long-term use of NSAIDs (risk of gastrointestinal perforation).
(3) High risk cardiovascular patients should be alert to arterial thrombosis, and those with bleeding tendencies should evaluate the benefit risk ratio.
5. Medication for special populations
(1) Breastfeeding period: Avoid breastfeeding during treatment and within 3 days after the last dose.
(2) Elderly: There is no significant difference in safety, but some patients may be more sensitive.
(3) Renal insufficiency: Mild to moderate without dose adjustment, severe without data.
Disclaimer：《Medication instructions for Nintedanib in Laos》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！